Quantitative Concept
Dispatch Bio Launches with $216M and CAR-T Pioneer Carl June to Advance Universal Solid Tumor Immunotherapy
Dispatch Bio; solid tumors; immunotherapy; CAR-T; Carl June; Series A funding; Flare platform; Parker Institute for Cancer Immunotherapy; ARCH Venture Partners; universal cancer treatment
AstraZeneca Highlights Survival Benefit for Tagrisso Combo Amid Competition in Lung Cancer
AstraZeneca; Tagrisso; lung cancer; Johnson & Johnson; EGFR-mutated NSCLC; overall survival; chemotherapy combination; FLAURA2 trial; life-extension benefit
Replimune’s Shares Plunge After FDA Rejects Melanoma Drug Application
Replimune; RP1; FDA rejection; melanoma; cancer drug; Complete Response Letter; clinical trial design; objective response rate; share price drop
Big Pharma Braces for Potential 200% US Tariffs Amid Uncertainty
pharmaceutical industry; tariffs; Donald Trump; supply chains; onshoring; drug prices; manufacturing; healthcare system
J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025
Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease
Veru Survey Highlights Muscle Loss Concerns Among GLP-1 Users as Lean Mass-Preserving Drug Advances
Veru; GLP-1 receptor agonists; muscle loss; enobosarm; lean mass; obesity; survey; older adults; high-protein diet
Recent Developments in Building Measurable Patient Support Programs (2025)
patient support programs; measurable outcomes; collaborative healthcare; 2025 trends; Medicare reforms; cost efficiency; access to care
FDA Commissioner Makary Proposes Fast-Track Drug Review Vouchers Tied to Lower US Prices, Without Detailing Criteria
FDA; Makary; national priority review vouchers; drug pricing; fast-track approval; price parity; pilot program
Pfizer, Astellas’ Xtandi Combo Extends Survival in Early Prostate Cancer
Pfizer; Astellas; Xtandi; Enzalutamide; prostate cancer; overall survival; combination therapy; leuprolide; non-metastatic hormone-sensitive prostate cancer (nmHSPC); EMBARK study; biochemical recurrence (BCR)
Nimble radiopharma biotech Actithera secures $75M Series A to enter the clinic
Actithera; radiopharma; Series A; biotech funding; clinic entry; Andreas Goutopoulos; startup financing